Skip to main content
OpenTrials
Completed

NCT Number: NCT04284072

Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology

Clinically validate a biopotential and motion recording wearable device (Byteflies Sensor Dot) for detection of epileptic seizures in the epilepsy monitoring unit (EMU) and at home.

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospitals Leuven, department of Neurology, Leuven, Belgium

Loading trial locations.

About this study

Subjects with refractory epilepsy who are admitted to the Epilepsy Monitoring Unit (EMU) for clinically-indicated long-term video-EEG assessment will be simultaneously monitored with Sensor Dots to record electroencephalographic (EEG), electrocardiographic (ECG), electromyographic (EMG), and motion signals.

A subset of subjects will continue using Sensor Dot devices at home (Home Phase) after completing the EMU Phase.

The data recorded by Sensor Dots will be used to: 1) annotate epileptic seizures, which will be compared to the annotations made as part of routine EMU monitoring and seizure diaries kept at home, and 2) to develop seizure detection algorithms. The data collected as part of this study will not be used to influence clinical decision making.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects (4+ years old) with refractory epilepsy who are admitted to the hospital for clinically-indicated long-term video-EEG assessment or presurgical evaluation, and a high likelihood of experiencing seizures during the EMU Phase
  • For subjects continuing into the Home Phase: successful recording of their habitual seizures with Sensor Dot during the EMU Phase
  • For subjects continuing into the Home Phase: the ability to keep an e-diary

Exclusion criteria

  • Known allergies to any of the biopotential electrodes or adhesives used as part of the study protocol
  • Having an implanted device, such as (but not limited to) a pacemaker, cardioverter defibrillator (ICD), and/or neural stimulation device because Sensor Dot contains magnets that could interfere with the operation of these devices
  • Women who are pregnant

Treatment and study plan

Sensor Dot

Device

Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).

Primary outcomes

  1. Comparison of typical absence seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during wakefulness

    Time frame: up to two weeks

    F1-score as determined by expert reviewers

  2. Comparison of typical absence seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during sleep

    Time frame: up to two weeks

    F1-score as determined by expert reviewers

  3. Comparison of focal impaired awareness seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during wakefulness

    Time frame: up to two weeks

    F1-score as determined by expert reviewers

  4. Comparison of focal impaired awareness seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during sleep

    Time frame: up to two weeks

    F1-score as determined by expert reviewers

  5. Comparison of tonic-clonic seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during wakefulness

    Time frame: up to two weeks

    F1-score as determined by expert reviewers

  6. Comparison of tonic-clonic seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during sleep

    Time frame: up to two weeks

    F1-score as determined by expert reviewers

Secondary outcomes

  1. Sensor Dot usability

    Time frame: up to two weeks

    We will assess the usability of the device as perceived by users (patients and healthcare personnel) via surveys

  2. To assess seizure duration

    Time frame: up to two weeks

    From the Sensor Dot data, we will be able to assess seizure duration

  3. To assess the usability of the seizure e-diary

    Time frame: up to two weeks

    We will asses usability of the electronic seizure diary

  4. To evaluate the accuracy of automated seizure detection algorithms

    Time frame: 2 years

    We will use the collected data and seizure annotations to develop algorithms to automatically detect epileptic seizures. We plan to evaluate how accurate these new automated seizure detection algorithms are.

  5. Comparison of seizure annotations derived from Sensor Dot data collected during the Home Phase against seizure diary annotations

    Time frame: up to 2 weeks

    Accuracy as determined by expert reviewers

  6. Sensor Dot Performance

    Time frame: up to 2 weeks

    We will assess the technical performance of the device by comparing the actual length of recorded data against the expected recording length, and what percentage of the data is high quality enough to make seizure annotations.

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Collaborators

  • Byteflies
  • Freiburg University
  • Helpilepsy
  • Karolinska Institutet
  • King's College London
  • Oxford University Hospitals NHS Trust
  • RWTH Aachen University
  • UCB Pharma
  • University of Coimbra

Registry information

Official study title

A Multicenter Study to Examine Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology

Acronym: SeizeIT2

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Feb 25, 2020
Registry last updated
Nov 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.